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ABSTRACT 46 
Background: Emerging evidence suggests that increasing intakes of nitrate-rich vegetables 47 
may be an effective approach to reducing blood pressure. 48 
Objective: Our primary aim was to determine whether daily consumption of nitrate-rich 49 
vegetables over 4 weeks would result in lower blood pressure. 50 
Design: Thirty participants with pre-hypertension or untreated grade 1 hypertension were 51 
recruited to a randomised, controlled, crossover trial with 4-week treatment periods separated 52 
by 4-week washout periods. Participants completed three treatments in random order: (1) 53 
increased intake (~200 g/d) of nitrate-rich vegetables (high nitrate, HN, ~150 mg/d nitrate); 54 
(2) increased intake (~200 g/d) of nitrate-poor vegetables (low nitrate, LN, ~22 mg/d nitrate); 55 
and (3) no increase in vegetables (control, C, ~6 mg/d nitrate). Compliance was assessed 56 
using food diaries and by measuring plasma nitrate and carotenoids. Nitrate metabolism was 57 
assessed using plasma, salivary, and urinary nitrate and nitrite concentrations. The primary 58 
outcome was blood pressure assessed using 24-hour ambulatory, home, and clinic 59 
measurements. Secondary outcomes included measures of arterial stiffness. 60 
Results: Plasma nitrate and nitrite concentrations were increased with the HN treatment in 61 
comparison to the LN and control treatments (P<0.001). Plasma carotenoids were increased 62 
with the HN and LN treatments compared to the control (P<0.01). High nitrate treatment did 63 
not reduce systolic blood pressure (24-hour ambulatory: HN 127.4±1.1 mmHg, LN 128.6±1.1 64 
mmHg, C 126.2±1.1 mmHg, P=0.20; home: HN 127.4±0.7 mmHg, LN 128.7±0.7 mmHg, C 65 
128.3±0.7 mmHg, P=0.36; clinic: HN 128.4±1. 3mmHg, LN 130.3±1.3 mmHg, C 129.8±1.3 66 
mmHg, P=0.49) or diastolic blood pressure compared with LN and C treatments (P>0.05) 67 
after adjustment for pre-treatment values, treatment period and treatment order. Similarly, no 68 
differences were observed between treatments for arterial stiffness measures (P>0.05). 69 
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Conclusion: Increased intake of nitrate-rich vegetables did not lower blood pressure in pre-70 
hypertensive or untreated grade 1 hypertensive individuals when compared with increased 71 
intake of nitrate-poor vegetables and no increase in vegetables. 72 
Clinical trial registry number and website: This trial was prospectively registered at 73 
www.anzctr.org.au as ACTRN12615000194561. 74 
Keywords: blood pressure, vascular stiffness, nitrate, vegetables, hypertension  75 
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INTRODUCTION 76 
High blood pressure is the leading risk factor for global disease burden (1). The maintenance 77 
of a healthy blood pressure and the prevention of hypertension continues to be a public health 78 
priority worldwide (2, 3). It is estimated that for every 10 mmHg reduction in systolic blood 79 
pressure there is a 13-28% lower risk of cardiovascular disease events and all-cause mortality 80 
(4). Arterial stiffness, which is closely related to hypertension (5, 6), is also a predictor of 81 
cardiovascular and all-cause mortality (7). Diets rich in vegetables, such as the vegetarian diet 82 
(8), Mediterranean diet, Nordic diet, and Dietary Approaches to Stop Hypertension (DASH) 83 
diet (9), have been shown to lower blood pressure. There are many components of a diet rich 84 
in vegetables that may benefit cardiovascular health. In particular, emerging evidence 85 
suggests that inorganic nitrate found in vegetables can contribute to lowering blood pressure 86 
(10, 11). 87 
Inorganic nitrate is a precursor for nitric oxide (NO) (12). Nitric oxide is an important cell 88 
signalling molecule and potent vasodilator critical for vascular health (13). The enterosalivary 89 
nitrate-nitrite-NO pathway generates NO via the sequential reduction of the anions nitrate and 90 
nitrite. This is facilitated by facultative anaerobic bacteria in the oral cavity, the acidic 91 
environment of the stomach and numerous endogenous molecules identified as having nitrite 92 
reducing ability (14). Increased scavenging of NO and dysfunction of the L-arginine-NO 93 
pathway underlie the reduced bioavailability of NO observed in hypertensive individuals (15). 94 
Increasing plasma nitrate through dietary means may provide a new therapeutic measure for 95 
restoring NO levels.  96 
Vegetables account for approximately 80% of total nitrate consumed in the general 97 
population, with the majority coming from leafy green vegetables and beetroot (12, 16). There 98 
is now consistent and convincing evidence that an increase in nitrate salts and nitrate-rich 99 
vegetables can result in a decrease in blood pressure within hours of ingestion (10, 11, 17-19). 100 
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However, data from short-term trials are yet to provide a clear understanding of the effects of 101 
a chronic increase in nitrate intake on blood pressure (10). In particular, there is a need to 102 
determine whether increasing nitrate-rich vegetables results in sustained lower blood pressure 103 
in individuals with elevated blood pressure. The results of published studies in this population 104 
are inconsistent (19, 20). 105 
The objective of this study was to investigate whether increased intake of nitrate-rich 106 
vegetables would result in lower blood pressure and improved arterial stiffness. An increased 107 
intake of nitrate-rich vegetables was compared with a matching increase in nitrate-poor 108 
vegetables, and no increase in vegetables.  109 
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METHODS 110 
Ethics 111 
The Vegetable Intake and Blood Pressure (VIABP) study (registered at www.anzctr.org.au as 112 
ACTRN12615000194561) was approved by the University of Western Australia Human 113 
Research Ethics Committee and was carried out in accordance with the Declaration of 114 
Helsinki. Written informed consent was obtained from all participants.  115 
Trial design 116 
The VIABP study was a randomised, controlled, crossover trial with three 4-week treatment 117 
periods, each preceded by a 4-week washout period (Supplemental Figure 1). The study was 118 
conducted at the Royal Perth Hospital Medical Research Foundation, Perth, Australia. 119 
Participants were randomly assigned to one of six sequence orders for the three treatments 120 
using computer-generated random numbers, assigned upon randomisation. The three 121 
treatments were: (1) increased intake of nitrate-rich vegetables (high nitrate diet, ~200 g/d); 122 
(2) increased intake of nitrate-poor vegetables (low nitrate diet, ~200 g/d); and (3) no increase 123 
in vegetables (control diet). Throughout the entire 24-week trial period all participants were 124 
asked to limit their intake of nitrate-rich vegetables, except whilst undertaking the high nitrate 125 
treatment (Supplemental Table 1). 126 
Participants 127 
Thirty participants with pre-hypertension or untreated grade 1 hypertension were recruited 128 
from the Perth general population using newspaper advertisements between March and July 129 
2015. Participants were ambulant men and women between the ages of 21 and 75 years, with 130 
a resting mean systolic blood pressure between 120-160 mmHg, inclusive. Participants were 131 
excluded if they were: diabetic; a smoker; taking antihypertensive medication, nitric oxide 132 
donors, organic nitrates and nitrites, or related drugs; had a body mass index (BMI) ≥35 kg/m2 133 
or <18.5 kg/m2; or used antibacterial mouth wash. For a complete list of inclusion and 134 
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exclusion criteria see Supplemental Table 2. Participants underwent screening procedures 135 
consisting of anthropometric measurements (height, weight, waist circumference, and hip 136 
circumference), an electrocardiogram, and a fasting blood test, which consisted of a full blood 137 
count, lipid profile, and glucose test, analysed by PathWest laboratories (Royal Perth 138 
Hospital, Perth, Australia). Blood pressure was assessed using a Dinamap 1846SX/P 139 
oscillometric recorder (Critikon Inc., Tampa, FL, USA). Participants were asked to rest for 5 140 
minutes before five blood pressure and heart rate readings were taken at 2 minute intervals. 141 
The first measurement was excluded and the mean of the next four consecutive readings was 142 
used to determine resting blood pressure. After blood tests confirmed eligibility, participants 143 
were asked to return to the research clinic to complete a medical examination by one of our 144 
physicians (IBP and LJB). Participants provided a list of current medications and 145 
supplements, and a medical history. At the same visit, participants completed a validated food 146 
frequency questionnaire (Dietary Questionnaire for Epidemiological Studies Version 2, 147 
DQES v2) (21-23) to obtain baseline dietary intake. Participants were supervised by a 148 
nutritionist whilst completing the questionnaire. Food models, food charts, measuring cups, 149 
and measuring spoons were provided to ensure the accuracy of reported food consumption. 150 
Dietary interventions 151 
During each 4-week treatment period, additions were made to participants’ breakfast and 152 
dinner, consisting of vegetables blended into juices or a matching control juice. Participants 153 
were asked to maintain all meals as usual with the exception of limiting high nitrate 154 
vegetables where possible. In the high and low nitrate treatment periods participants were 155 
asked to consume 100 g/d of high and low nitrate vegetables, respectively, before breakfast 156 
and dinner. This was equivalent to increasing vegetable intake by approximately 2.7 serves/d 157 
(~200-300 kJ/d) (24). For the control treatment, participants were asked to blend a quarter of 158 
an orange and 8 g maltodextrin in water (approximately energy matched to the vegetables 159 
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consumed in the high and low nitrate treatments). Prior to randomisation, participants 160 
consumed a sample juice for all three treatments and completed a juice acceptability 161 
questionnaire to ensure willingness to participate. They were provided with blenders and 162 
blended at least three different vegetables of approximate equal weight with a quarter of an 163 
orange (for taste) and less than 1 cup (~200 ml) of water. For the low nitrate treatment, 164 
participants were instructed they could microwave, oven bake, boil, or steam any low nitrate 165 
root vegetables before consumption, and were asked not to add any condiments (e.g. cooking 166 
oil, salt). The high and low nitrate vegetables consumed by participants are presented in 167 
Supplemental Table 3. Participants were asked to freeze a small sample of each treatment 168 
juice in a sterile 5 ml tube in the week prior to their post-treatment visit. Nitrate and nitrite 169 
concentrations were determined for each treatment juice. In addition, participants kept a diary 170 
of the type and weight of all vegetables (high nitrate and low nitrate) consumed in all 171 
prepared juices. Treatment diaries along with plasma concentrations of nitrate, nitrite, and 172 
total carotenoids were used to assess compliance. 173 
Clinical measurements 174 
Anthropometric measurements (body weight, waist circumference, and hip circumference) 175 
were assessed pre- and post-treatment. Participants were wearing minimal clothing and no 176 
shoes. Standing height (m) was measured without shoes using a wall-mounted stadiometer to 177 
the nearest 0.01 m. Fasting body weight (kg) was measured without shoes using electronic 178 
scales to the nearest 0.01 kg. Waist and hip circumference (cm) were measured using a steel 179 
tap measure (Lufkin Executive Thinline, W606PM, USA). Waist and hip measurements were 180 
used to calculate waist-to-hip ratio (waist cm / hip cm). 181 
Physical activity was assessed pre- and post-treatment using the validated short form of the 182 
International Physical Activity Questionnaire (IPAQ) (25). Total physical activity was 183 
calculated in MET-min/week and then converted to kJ/d. Alcohol intake was assessed pre- 184 
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and post-treatment using a 7 day alcohol diary. Standard drinks were calculated by 185 
multiplying the volume of alcohol consumed (L), the percentage of alcohol consumed (%) 186 
and the specific gravity of ethyl alcohol (0.789). Alcohol was converted to g/d. 187 
Blood pressure 188 
Ambulatory blood pressure 189 
Ambulatory blood pressure and heart rate were monitored every 20 minutes during the day 190 
and every 30 minutes overnight for a 24-hour period commencing at the end of pre- and post-191 
treatment visits, as previously described (26). Measurements showing an error code or those 192 
with a pulse pressure of less than 20 mmHg were excluded from the analysis. Blood pressure 193 
traces that were missing more than four hourly means over the 24 hours were also excluded 194 
from the analysis. A minimum of 70% successful readings was considered a valid recording. 195 
Mean blood pressure was determined for the 24-hour, daytime (06:00-21:59), and night-time 196 
(22:00-05:59) period. 197 
Home blood pressure 198 
Participants were provided with a digital blood pressure monitor (UA-767PC, A&D Co., Ltd, 199 
Saitama, Japan) and an appropriately sized upper-arm cuff. Participants were given 200 
appropriate training and instructions on its use prior to the study commencing. Home blood 201 
pressure was measured and recorded by each participant three times daily (shortly after 202 
waking and prior to breakfast, 1-2 hours prior to dinner, and 1-2 hours after dinner) for the 203 
entire study duration. Participants were instructed to rest for 5 minutes prior to commencing 204 
three blood pressure readings over a 3-minute period. The first measurement was excluded 205 
from the analysis and the mean of the second and third measurements used. Mean blood 206 
pressure was determined for the overall 4-week pre- and post-treatment periods; week 1, week 207 
2, and week 3 of each treatment; the last 7 days pre- and post-treatment period; and the 208 
morning, afternoon, and evening of the last 7 days pre- and post-treatment period. 209 
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Clinic blood pressure 210 
Clinic blood pressure was measured pre- and post-treatment using the SphygmoCor XCEL 211 
device (2012 AtCor Medical Pty. Ltd., Sydney, Australia). An appropriately sized blood 212 
pressure cuff was fitted to each participant’s non-dominant arm approximately 2.5 cm above 213 
the antecubital fossa. Participants were fasting for at least 12 hours and were asked to rest in a 214 
supine position for 5 minutes prior to three blood pressure measurements performed at 60 215 
second intervals. The first blood pressure reading was excluded and the mean of the second 216 
and third measurements used in analysis. 217 
Arterial stiffness 218 
Pulse wave analysis (PWA) and pulse wave velocity (PWV) were measured pre- and post-219 
treatment using the SphygmorCor XCEL device (2012 AtCor Medical Pty. Ltd., Sydney 220 
Australia). Participants were fasting for at least 12 hours, and avoided vigorous exercise and 221 
alcohol intake for at least 24 hours prior to assessment. Participants were asked to rest for 5 222 
minutes in a supine position before three blood pressure measurements at 60 second intervals 223 
were taken. Clinic blood pressure was followed by one 10 second capture PWA reading, 224 
which included central aortic systolic pressure, central aortic diastolic pressure, and 225 
augmentation index (%). An appropriately sized cuff was then fitted to the participants’ right 226 
thigh. Tubing was attached and a probe placed on the carotid artery. When a pulse was 227 
detected the femoral cuff inflated and captured aortic PWV. Two PWV measurements were 228 
taken and the average used in the analysis. If a >0.5 m/s difference between the first two 229 
measurements was observed, a third measurement was taken and the middle value of the three 230 
measurements was used. 231 
Biochemical analyses 232 
Fasting (≥12 hours) blood, saliva, and urine samples were collected pre- and post-treatment. 233 
Blood samples were collected by venepuncture into EDTA and Lithium Heparin Plasma with 234 
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Gel (LH PST II) tubes. Whole blood was centrifuged at 4⁰C, 3500 rpm for 10 minutes and 235 
plasma aliquots stored at -80⁰C until analysis. Participants spat into sterile polystyrene jars for 236 
5 minutes to obtain saliva samples and saliva aliquots stored at -80°C until analysis. Spot 237 
urine samples were also collected into sterile polystyrene jars and aliquots stored at -80°C 238 
until analysis.  239 
Nitrate and nitrite analysis 240 
Nitrate and nitrite concentrations were measured in plasma, saliva, urine, and juice samples 241 
using gas chromatography/mass spectrometry (GCMS) with 15N-labelled nitrate and nitrite as 242 
internal standards, as previously described (27). 243 
Plasma carotenoid analysis 244 
High-performance liquid chromatography (HPLC) methodology was used to determine 245 
plasma carotenoid concentrations of β-carotene, lycopene, α-carotene, β-cryptoxanthin, and 246 
lutein/ zeaxanthin, as previously described (28). Carotenoids were extracted using ethanol, 247 
ethyl acetate, and hexane, with canthaxanthin as an internal standard. Following evaporation 248 
of the solvents, the dried extract was reconstituted in dichloromethane: methanol (1:2 /vol) 249 
and chromatography performed on an Agilent 1200 HPLC system using Hypersil ODS 250 
column (100 mm X 2.1 mm X 5 um). Carotenoids were analysed using a mobile phase of 251 
acetonitrile: dichloromethane: methanol 0.05% ammonium acetate (85:10:5 v/v) at a flow rate 252 
of 0.3 mL/min, using a diode array detector (450 nm). 253 
Other biochemical analyses 254 
Urinary concentrations of sodium, potassium, and creatinine as well as plasma concentrations 255 
of sodium, potassium, creatinine, glucose, total cholesterol, high-density lipoprotein (HDL) 256 
cholesterol, triglycerides, and calculated low-density lipoprotein (LDL) cholesterol were 257 
analysed by PathWest laboratories (Fiona Stanley Hospital, Perth, Australia). 258 
Statistics 259 
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Sample size 260 
The required sample size for the study was based on the primary outcome of blood pressure 261 
measured using 24-hour ambulatory monitoring. It was estimated 25 participants would 262 
provide >80% power to detect a 2.0 mmHg difference in mean 24-hour systolic blood 263 
pressure, based on data from our previous studies (29, 30). This calculation assumes a type I 264 
error rate of 0.05/3 (0.017). In addition, we had >80% power to detect a 2.0 mmHg difference 265 
in mean home systolic blood pressure, based on data from our previous studies (29, 30).  266 
Statistical methods 267 
Global statistical significance was set at a 2-sided Type 1 error rate of P<0.05. All data were 268 
analysed using IBM SPSS Statistics for Windows, version 21.0 (IBM) and SAS software, 269 
version 9.4 (SAS Institute Inc.). Normality of distributions was tested using the Shapiro-Wilk 270 
normality test. Descriptive statistics of normally distributed continuous variables were 271 
expressed as mean ± standard deviation (SD), non-normally distributed continuous variables 272 
were expressed as median and interquartile range, and categorical variables as number and 273 
proportion (%). Differences between treatments (high nitrate, low nitrate, and control) were 274 
tested for each outcome variable using a repeated measures mixed model (proc mixed 275 
command) with additional adjustments for outcome pre-treatment values, treatment period 276 
and treatment order. We tested for any carryover effects between treatment periods using a 277 
treatment*treatment period interaction term.  278 
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RESULTS 279 
Recruitment began on 25 May 2015 and final data was collected on 5 May 2016. Of the 65 280 
participants screened for the study, 32 participants were randomised of whom 30 completed 281 
the study. Two participants withdrew after randomisation due to medical reasons unrelated to 282 
the trial (Figure 1). 283 
Baseline demographic and clinical characteristics for the 30 participants are shown in Table 284 
1. Baseline dietary data is shown in Supplemental Table 4. At baseline, the mean (SD) total 285 
nitrate, estimated using a nitrate content of vegetables database (31) as well as published food 286 
composition data, was 84.7 (36.2) mg/d (81.9% from vegetables alone). The mean (SD) total 287 
vegetable intake was 181.8 (75.8) g/d. Using participants’ food diaries from each treatment 288 
period, the median (IQR) reported increase in nitrate-rich vegetables for the high nitrate 289 
treatment was 201.5 (198.7-204.1) g/d and the increase in nitrate-poor vegetables for the low 290 
nitrate treatment was 201.7 (197.0-207.7) g/d. Descriptive statistics for the individual nitrate-291 
rich and nitrate-poor vegetables consumed in both the high and low nitrate treatments are 292 
shown in Supplemental Table 3. The median (IQR) nitrate and nitrite concentrations, from 293 
the juice samples provided by participants, and in which the participants were estimated to be 294 
consuming, were: 149.1 (118.2-237.0) and 3.96 (2.19-5.20) mg/d for the high nitrate 295 
treatment (n=30); 21.5 (13.9-29.9) and 0.31 (0.16-0.48) mg/d for the low nitrate treatment 296 
(n=27); and 5.5 (3.7-8.0) and 0.06 (0.05-0.08) mg/d for the control (n=29), respectively. 297 
Nitrate and nitrite concentrations were significantly different between treatment juices 298 
(P<0.001 for both). High nitrate juices were 27-fold higher in nitrate and 66-fold higher in 299 
nitrite concentration than that of the control (P<0.001 for both). In addition, the high nitrate 300 
juices were 6.9-fold higher in nitrate and 12.8-fold higher in nitrite concentration than that of 301 
the low nitrate juices (P<0.001 for both). The low nitrate and control juices were not different 302 
in nitrate (P=0.326) and nitrite (P=0.779) concentrations. 303 
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Compliance  304 
Compliance was measured for the three treatments using self-reported food diaries. 305 
Participants recorded the weight (g) of each vegetable consumed in their juice on a daily 306 
basis. Compliance was calculated by dividing the number of days the vegetables were 307 
consumed by the number of days the vegetables should have been consumed and then 308 
multiplying by 100. On the basis of reported consumption of treatments using food diaries, 309 
the median (IQR) compliance was 98.1 (90.6-100.0%) for the high nitrate treatment, 98.1% 310 
(92.9-100.0%) for the low nitrate treatment, and 98.1% (96.0-100.0%) for the control 311 
treatment. Compliance for the control diet was also measured by dividing the amount (g) of 312 
returned maltodextrin by the amount (g) of maltodextrin administered to participants before 313 
their treatment period and then multiplying by 100. On the basis of returned maltodextrin, the 314 
median (IQR) compliance was 131.5% (110.7-142.5%). All treatment diets were well 315 
tolerated. Whilst on the control treatment, one participant reported constipation symptoms and 316 
another reported loose stools. No serious adverse events were reported. 317 
Biomarkers of intake and metabolism 318 
Plasma nitrate and nitrite 319 
Median (IQR) plasma nitrate and nitrite concentrations pre- and post-treatment are shown in 320 
Table 2. Plasma nitrate was significantly different between treatments (P<0.001) (Figure 2). 321 
There was a 1.7-fold increase in plasma nitrate concentrations for the high nitrate treatment 322 
compared to the low nitrate treatment (P<0.001) and a 1.6-fold increase for the high nitrate 323 
treatment compared to control (P<0.001) (Figure 2). Plasma nitrite was significantly different 324 
between treatments (P=0.007) (Figure 2). There was a 1.5-fold increase in plasma nitrite 325 
concentrations for the high nitrate treatment compared to the low nitrate treatment (P=0.002) 326 
and a 1.3-fold increase for the high nitrate treatment compared to control (P=0.037) (Figure 327 
2). 328 
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Salivary nitrate and nitrite 329 
Median (IQR) salivary nitrate and nitrite concentrations for pre- and post-treatment are shown 330 
in Table 2. Salivary nitrate was significantly different between treatments (P=0.038) (Figure 331 
2). There was a 1.7-fold increase in salivary nitrate concentrations for the high nitrate 332 
treatment compared to the low nitrate treatment (P=0.022) and a 1.6-fold increase for the high 333 
nitrate treatment compared to control (P=0.036) (Figure 2). Salivary nitrite was not 334 
significantly different between treatments (P=0.098) (Figure 2).  335 
Urinary nitrate and nitrite 336 
Median (IQR) urinary nitrate and nitrite concentrations adjusted for urinary creatinine are 337 
presented in Table 2. Urinary nitrate was significantly different between treatments (P<0.001) 338 
(Figure 2). There was a 1.9-fold increase in urinary nitrate concentration for the high nitrate 339 
treatment compared to the low nitrate treatment (P<0.001) and a 1.8-fold increase for the high 340 
nitrate treatment compared to the control (P<0.001) (Figure 2). Urinary nitrite was not 341 
significantly different between treatments (P=0.074) (Figure 2).  342 
Plasma carotenoids 343 
Descriptive statistics for plasma total carotenoids, lutein, beta-cryptoxanthin, lycopene, alpha-344 
carotene, and beta-carotene are presented in Table 3. Plasma total carotenoids were 345 
significantly different between treatments (P<0.001) (Figure 3). There was a 1.4-fold increase 346 
in the high nitrate treatment compared to the control (P<0.001) and a 1.3-fold increase in the 347 
low nitrate treatment compared to the control (P=0.002) (Figure 3). Plasma lutein was 348 
significantly different between treatments (P<0.001) (Figure 3). There was a 1.6-fold increase 349 
in plasma lutein in the high nitrate treatment compared to the low nitrate treatment (P<0.001) 350 
and a 1.8-fold increase in the high nitrate treatment compared to the control (P<0.001) (Figure 351 
3). Plasma beta-carotene was significantly different between treatments (P=0.002) (Figure 3). 352 
There was a 1.6-fold increase in plasma beta-carotene in the high nitrate treatment compared 353 
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to the control (P=0.002) and a 1.6-fold increase in the low nitrate treatment compared to the 354 
control (P=0.003) (Figure 3). Plasma beta-cryptoxanthin, lycopene, and alpha-carotene were 355 
not significantly different between treatments (Figure 3).  356 
Plasma and urinary sodium and potassium 357 
Plasma and urinary sodium and potassium, and urinary sodium to potassium ratio were not 358 
significantly different between treatments (Table 4). 359 
Blood pressure 360 
Ambulatory blood pressure 361 
Ambulatory measures of blood pressure were excluded for 2 (6.7%) participants due to 362 
equipment malfunction (n=1) and <70% successful readings (n=1). The mean (SD) 24-hour, 363 
daytime, and night-time ambulatory measures of blood pressure and heart rate pre- and post-364 
treatment are presented in Table 5. There were no significant differences between treatments 365 
for mean 24-hour, daytime, or night-time ambulatory blood pressure and heart rate (Figure 366 
4). No carryover effects were observed for 24-hour, daytime, and night-time ambulatory 367 
measures of blood pressure and heart rate (P>0.05 for all). In a post-hoc sensitivity analysis in 368 
which we adjusted for age, gender and BMI, the results were very similar and not 369 
substantively changed (data not shown). 370 
Home blood pressure 371 
Home measures of blood pressure were complete for all participants. Mean (SD) home 372 
measures of blood pressure and heart rate pre- and post-treatment are presented in Table 5. 373 
There were no significant differences between treatments for blood pressure and heart rate for 374 
the last 7 days of treatment (Figure 4). There were also no significant differences between 375 
treatments for blood pressure and heart rate for week 1, week 2 and week 3 of treatment when 376 
analysed separately (Figure 5). In addition, we found no significant differences between 377 
treatments for blood pressure and heart rate measured in the morning, afternoon, and evening 378 
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when analysed separately (data not shown). Mean daily home measures of blood pressure and 379 
heart rate are shown in Supplemental Figure 2.  No carryover effects were observed for 380 
home measures of blood pressure and heart rate (P>0.05 for all). 381 
Clinic blood pressure 382 
Clinic measures of blood pressure were complete for all participants. Mean (SD) clinic 383 
measures of blood pressure and heart rate pre- and post-treatment are presented in Table 5. 384 
There were no significant differences between treatments for blood pressure and heart rate 385 
(Figure 4).  386 
Arterial stiffness 387 
Pulse wave analysis was complete for all participants. Pulse wave velocity was incomplete for 388 
4 (13.3%) participants due to an inability to obtain measurements. Mean (SD) central systolic 389 
and diastolic pressures, central augmentation index (%), and pulse wave velocity for pre- and 390 
post-treatment are shown in Table 6. No significant differences were observed between 391 
treatments for central systolic blood pressure, central diastolic blood pressure, central 392 
augmentation index, and pulse wave velocity. 393 
Plasma lipids and glucose 394 
Plasma total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, and glucose were 395 
not significantly different between treatments (Table 4). 396 
Anthropometry, physical activity and alcohol intake 397 
Descriptive statistics for anthropometry, physical activity, and alcohol intake pre- and post-398 
treatment are presented in Supplemental Table 5. Weight, BMI, waist circumference, hip 399 
circumference, and waist-to-hip ratio were not significantly different between treatments. 400 
Physical activity expended in kJ/d and alcohol consumed in the last 7 days prior to each 401 
treatment period were also not significantly different between treatments.  402 
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DISCUSSION 403 
In this 4-week randomised controlled crossover trial, an additional ~200 g/d intake of nitrate-404 
rich vegetables did not alter blood pressure or arterial stiffness in men and women with pre-405 
hypertension or untreated grade 1 hypertension. There was a significant increase in salivary, 406 
urinary, and plasma nitrate as well as plasma nitrite concentrations after the high nitrate 407 
treatment, confirming the dietary interventions were effective in altering nitrate 408 
concentrations. In addition, total plasma carotenoids were increased with increased 409 
consumption of both high and low nitrate vegetables. Our study findings did not support our 410 
hypothesis that an increased intake of high nitrate vegetables would result in lower blood 411 
pressure and improved arterial stiffness.  412 
A number of short-term trials have assessed the effects of increased nitrate intake on blood 413 
pressure (10, 11).  The results of these studies are inconsistent, with several trials finding 414 
lower blood pressure with increased nitrate intake (19, 32-37), and others finding no effect 415 
(20, 38-42). Our study is unique in that the design assessed the impact of a sustained 4-week 416 
increase in nitrate-rich vegetables in individuals with pre-hypertension or untreated grade 1 417 
hypertension and that subjects were not taking anti-hypertensive medication which could have 418 
modified any effect of nitrate. There are many potential factors that could influence whether 419 
an increase in nitrate intake results in lower blood pressure. The duration of the study appears 420 
to be a factor, with acute studies consistently showing blood pressure lowering effects (17, 421 
42-53). Other factors may include the dose of nitrate provided; the background nitrate and 422 
vegetable intake of the study participants, which may alter the effective dose; whether there is 423 
an individual threshold level, beyond which there is little additional benefit; and the age and 424 
health status of the participants. 425 
Only three studies have investigated the short-term sustained effects of nitrate ingestion on 426 
blood pressure and arterial stiffness over a period of four or more weeks (19, 33, 42). Of 427 
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these, only one has investigated the effects in pre-hypertensive or untreated hypertensive 428 
individuals (19). Kapil et al (19) found daily consumption of beetroot juice (nitrate dose: 398 429 
mg/d or 6.4 mmol/d) reduced blood pressure and improved arterial stiffness in 64 untreated or 430 
treated hypertensive individuals. Although our study does not align with the aforementioned 431 
study (19), other short-term intervention studies (3-42 days) have demonstrated no effect of 432 
nitrate ingestion on blood pressure (20, 38-42) or arterial stiffness (40, 41). These studies 433 
were all in individuals at risk for cardiovascular disease (20, 38-42). Previous trials where 434 
improvements have been observed in blood pressure and arterial stiffness with increased 435 
nitrate intake have been a mix of healthy participants (34-37) and those at risk of 436 
cardiovascular disease (19, 32, 33, 42). There is strong evidence to show that nitrate ingestion 437 
reduces blood pressure within hours of ingestion (17, 42-53). The acute effects on arterial 438 
stiffness are less clear. Some studies demonstrate improvements (42, 44, 53) while others do 439 
not (47, 50, 51, 54). 440 
Several factors may explain why our study did not demonstrate a reduction in blood pressure. 441 
As mentioned previously, background diet may have influenced nitrate metabolism with 442 
individuals having sufficient nitrate intake unresponsive to further nitrate supplementation. 443 
Possible interactions between nitrate and sulphur-containing dietary constituents have been 444 
proposed (55). Nitrate in drinking water was inversely associated with blood pressure at low 445 
sulphate concentrations (9-33 mg/L), but this relationship reversed at medium to high 446 
concentrations (34-102 mg/L). Such an interaction would unlikely to have confounded the 447 
results of our study as the calculated mean sulphate concentration in water consumed by our 448 
cohort was 13.5 mg/L (data not shown). This data, however, does not fully discount such an 449 
interaction as sulphur-containing foods within the diet cannot be calculated due to the absence 450 
of adequate nutrient databases. In addition, Montenegro et al (56) has recently demonstrated 451 
acid suppressing drugs abolished the blood pressure lowering effects of oral nitrite ingestion 452 
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despite the increase in plasma nitrite concentration. Only one participant in our study reported 453 
taking an acid suppressing drug (Rabeprazole) for the treatment of gout. This does not 454 
discount the theory that gastric pH may differ between individuals and that it is a possible 455 
determinant in influencing blood pressure after nitrate ingestion.  456 
Limitations to this intervention study need to be considered. Firstly, we did not observe 457 
differences in urinary potassium concentrations. We may have expected to see a >10% 458 
increase in potassium excretion given the self-reported increases in vegetable intake. This 459 
could be the result of using creatinine-adjusted values from a spot urine instead of a 24-hour 460 
urine sample to assess urinary potassium (57). We did, however, observe a ~1.6 fold increase 461 
in plasma nitrate and nitrite with increased nitrate-rich vegetables and a ~1.4 fold increase in 462 
plasma total carotenoids with increased nitrate-rich and nitrate-poor vegetables. The increase 463 
in plasma nitrate, nitrite, and total carotenoids gives us confidence the participants were 464 
compliant. It should be noted that plasma nitrite concentrations in our study are higher than 465 
some reported values in the literature. This could be due to a number of factors; however, it is 466 
likely an outcome of the GCMS method compared to gas phase chemiluminescence (27). 467 
Secondly, our study demonstrated no statistical difference in salivary and urinary nitrite 468 
concentrations. Circulating nitrate and nitrite concentrations depend on when nitrate is last 469 
ingested. The half-life of nitrate in plasma is 5-6 hours (58). Nitrite is likely to be similar as 470 
new nitrite is being continuously generated from the ingested nitrate. As participants were 471 
asked to fast for at least 12 hours prior to providing samples, this may explain why no 472 
increases in salivary and urinary nitrite concentrations were observed. However, other 473 
mechanisms may explain this observation and warrants further investigation. Thirdly, the 474 
estimated nitrate intake from the measured juice samples was 149 mg/d, whereas the 475 
estimated nitrate intake using a comprehensive international nitrate database (31) was 326 476 
mg/d. The nitrate content of vegetables available in Perth may be appreciably lower than 477 
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many other regions of the world due to high intensity of sunlight and longer daylight hours. 478 
Vegetables grown in lower light intensity and fewer daylight hours have a tendency to 479 
accumulate higher nitrate concentrations (59, 60). Fourthly, due to the nature of the 480 
intervention, participants could not be blinded to the treatments received. Blinding was, 481 
however, utilised for all laboratory analyses. Lastly, we cannot rule out any small effects on 482 
blood pressure, less than approximately 2 mmHg. 483 
In summary, our findings suggest no short-term clinically significant effects on blood 484 
pressure, arterial stiffness, lipids and glucose from increasing the intake of nitrate-rich 485 
vegetables in men and women with pre-hypertension or untreated grade 1 hypertension. There 486 
are likely complex issues surrounding why no benefit was seen, including background nitrate 487 
intake, the level of increase in nitrate intake, cross-talk mechanisms and populations at risk of 488 
cardiovascular disease, which may all play a vital role in the differences observed between 489 
studies.  490 
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Table 1. Demographic and clinical characteristics of study participants at screening1 
 
All participants 
n = 30 
Demographics  
Male/female, n 20/10 
Age, years 63.0 [55.5-70.5] 
BMI, kg/m2 27.0 ± 3.9 
Waist circumference2, cm  89.5 ± 11.7 
Hip circumference2, cm  102.0 [95.0-104.5] 
Waist-to-hip ratio2  0.9 ± 0.1 
Smoking history2  11 (37.9) 
Medications  
HMG-CoA reductase inhibitors  5 (16.7) 
Clinic blood pressure  
Systolic blood pressure, mmHg 133.6 ± 8.4 
Diastolic blood pressure, mmHg 77.7 ± 8.0 
Heart rate, bpm 61.6 ± 8.0 
Biochemistry  
Total cholesterol, mmol/L 5.5 [4.3-6.3] 
Triglycerides, mmol/L 1.2 [0.8-1.7] 
LDL cholesterol, mmol/L 3.6 ± 1.2 
HDL cholesterol, mmol/L 1.3 ± 0.3 
Glucose, mmol/L 5.3 ± 0.4 
1Results are displayed as mean ± SD, median [IQR] or n (%). BMI, body mass index; 
LDL, low density lipoprotein; HDL, high density lipoprotein. 
2n=29. 
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Table 2. Descriptive statistics for nitrate and nitrite concentrations in plasma, saliva and urine by treatment, and the between-treatment 
differences1 
 
C 
(n=30) 
LN 
(n=30) 
HN 
(n=30) 
Treatment effect2 
HN vs. C HN vs. LN 
Nitrate      
Plasma, µmol/L      
   Pre 22.4 [17.5-27.5] 23.5 [18.7-28.3] 23.0 [16.2-32.6]   
   Post 22.5 [19.0-30.2] 22.7 [15.2-27.2] 34.3 [26.1-52.1] 15.8 ± 4.13 16.7 ± 4.33 
Salivary, µmol/L      
   Pre 126.4 [48.5-194.1] 116.1 [35.8-197.3] 94.1 [38.1-152.4]   
   Post 107.9 [39.3-214.7] 75.6 [36.1-190.1] 134.8 [33.2-341.6] 91.5 ± 42.64 102.4 ± 43.34 
Urinary, µmol/mmol creatinine      
   Pre 48.8 [28.6-63.9] 38.2 [28.1-58.0] 42.9 [29.0-62.6]   
   Post 47.4 [30.2-73.5] 44.4 [29.7-58.4] 79.4 [47.8-138.8] 39.5 ± 10.73 43.0 ± 11.23 
Nitrite      
Plasma, µmol/L      
   Pre 2.1 [1.6-2.9] 2.1 [1.6-2.7] 2.3 [1.7-2.7]   
   Post 2.4 [1.9-3.2] 2.0 [1.4-2.5] 2.8 [2.2-4.2] 0.7 ± 0.34 1.1 ± 0.34 
Salivary, µmol/L      
   Pre 53.9 [17.0-112.0] 48.7 [18.9-101.0] 36.8 [15.0-67.8]   
   Post 61.0 [25.6-90.9] 41.9 [12.5-92.1] 67.0 [16.1-157.1] 29.5 ± 19.9 42.6 ± 20.04 
Urinary, µmol/mmol creatinine      
   Pre 6.7 [2.7-16.3] 9.3 [2.9-16.6] 8.2 [3.9-18.0]   
   Post 9.1 [4.1-18.0] 13.8 [3.2-22.9] 13.0 [3.5-38.0] 8.6 ± 3.84 6.4 ± 4.0 
1Results are presented as median [IQR]. n=30. C, control; LN, low nitrate; HN, high nitrate. 
2Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) 
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. 
3P<0.001. 
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4P<0.05. 
  
35 
 
 
Table 3. Descriptive statistics for plasma carotenoid concentrations by treatment, and the between-treatment differences1 
 
C 
(n=30) 
LN 
(n=30)2 
HN 
(n=30) 
Treatment effect3 
HN vs. C HN vs. LN 
Total carotenoids, mg/L      
   Pre 1.675 [1.200-2.212] 1.711 [1.360-2.457] 1.701 [1.305-2.205]   
   Post 1.613 [1.257-2.217] 1.850 [1.524-2.668] 2.131 [1.637-2.560] 0.658 ± 0.1704 0.073 ± 0.178 
Lutein, mg/L      
   Pre 0.316 ± 0.107 0.321 ± 0.114 0.303 ± 0.102   
   Post 0.313 ± 0.120 0.355 ± 0.120 0.547 ± 0.176 0.246 ± 0.0275 0.202 ± 0.0295 
Beta-cryptoxanthin, mg/L      
   Pre 0.337 [0.269-0.539] 0.387 [0.272-0.506] 0.361 [0.249-0.551]   
   Post 0.385 [0.292-0.504] 0.406 [0.310-0.736] 0.362 [0.306-0.547] -0.067 ± 0.047 -0.098 ± 0.049 
Lycopene, mg/L      
   Pre 0.036 [0.018-0.067] 0.041 [0.023-0.081] 0.042 [0.021-0.075]   
   Post 0.033 [0.023-0.065] 0.052 [0.018-0.084] 0.037 [0.022-0.069] -0.002 ± 0.005 0.010 ± 0.006 
Alpha-carotene, mg/L      
   Pre 0.047 [0.027-0.076] 0.047 [0.024-0.086] 0.056 [0.032-0.086]   
   Post 0.053 [0.033-0.081] 0.057 [0.027-0.089] 0.051 [0.023-0.071] -0.008 ± 0.006 -0.011 ± 0.006 
Beta-carotene, mg/L      
   Pre 0.797 [0.317-1.149] 0.781 [0.443-1.399] 0.737 [0.535-1.144]   
   Post 0.787 [0.365-1.040] 0.925 [0.528-1.602] 1.158 [0.630-1.460] 0.438 ± 0.1376 0.010 ± 0.144 
1Results are presented as mean ± SD or median [IQR]. n=30. C, control; LN, low nitrate; HN, high nitrate. 
2Low nitrate post treatment (n=29). 
3Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) 
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. 
4P<0.001. 
5P<0.0001. 
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6P<0.01 
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Table 4. Descriptive statistics for standard biochemical analyses by treatment, and the between-treatment differences1 
 
C 
(n=30) 
LN 
(n=30) 
HN 
(n=30) 
Treatment effect2 
HN vs. C HN vs. LN 
Plasma total cholesterol, 
mmol/L 
   
  
   Pre 5.5 ± 1.0 5.5 ± 1.2 5.5 ± 1.2   
   Post 5.6 ± 1.3 5.5 ± 1.2 5.3 ± 1.1 -0.33 ± 0.14 -0.23 ± 0.14 
Plasma triglycerides, mmol/L      
   Pre 1.0 [0.9-1.5] 1.1 [0.8-1.7] 1.1 [0.8-1.4]   
   Post 1.1 [0.9-1.6] 1.2 [0.9-1.8] 1.0 [0.7-1.6] -0.10 ± 0.07 0.14 ± 0.07 
Plasma LDL cholesterol, 
mmol/L 
     
   Pre 3.4 ± 0.9 3.4 ± 1.0 3.5 ± 1.1   
   Post 3.6 ± 1.1 3.5 ± 1.1 3.4 ± 1.0 -0.25 ± 0.12 0.15 ± 0.13 
Plasma HDL cholesterol, 
mmol/L 
     
   Pre 1.5 ± 0.4 1.4 ± 0.4 1.4 ± 0.3   
   Post 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 -0.03 ± 0.03 -0.03 ± 0.03 
Plasma glucose, mmol/L      
   Pre 5.1 ± 0.5 4.9 ± 0.4 5.0 ± 0.6   
   Post 5.0 ± 0.4 5.0 ± 0.4 5.0 ± 0.5 0.01 ± 0.08 -0.01 ± 0.08 
Plasma creatinine, mmol/L      
   Pre 69.9 ± 10.1 70.5 ± 10.6 70.1 ± 12.1   
   Post 70.5 ± 10.0 71.2 ± 11.2 69.2 ± 10.0 -1.35 ± 1.31 -2.14 ± 1.37 
Plasma sodium, mmol/L      
   Pre 137.0 [134.5-138.7] 137.3 [135.6-138.1] 137.0 [134.9-138.9]   
   Post 137.5 [134.9-138.9] 137.0 [135.7-138.1] 136.2 [133.3-138.4] -0.12 ± 1.2 -0.05 ± 1.29 
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Plasma potassium, mmol/L      
   Pre 4.1 ± 0.3 4.0 ± 0.3 4.0 ± 0.3   
   Post 4.0 ± 0.3 4.0 ± 0.3 3.9 ± 0.3 -0.07 ± 0.06 -0.03 ± 0.06 
Urinary sodium, mmol/mmol 
creatinine 
     
   Pre 8.2 [5.0-10.8] 8.3 [5.5-12.7] 8.9 [4.4-11.1]   
   Post 7.0 [4.7-11.3]  8.0 [6.6-11.1] 7.1 [5.3-10.5] 0.44 ± 1.05 -0.70 ± 1.10 
Urinary potassium, 
mmol/mmol creatinine 
     
   Pre 7.3 [5.9-8.7] 7.4 [5.9-10.0] 7.8 [5.6-10.1]   
   Post 8.1 [7.1-9.3] 7.8 [5.9-9.8] 8.1 [6.5-10.4] 0.22 ± 0.54 0.35 ± 0.56 
Urinary sodium/potassium 
ratio, mmol/mmol creatinine 
     
   Pre 1.0 [0.8-1.5] 1.1 [0.8-1.5] 0.9 [0.6-1.5]   
   Post 0.8 [0.6-1.3] 1.0 [0.8-1.5] 0.9 [0.6-1.3] 0.07 ± 0.11 0.12 ± 0.12 
1Results are presented as mean ± SD or median [IQR]. n=30. C, control; LN, low nitrate; HN, high nitrate. 
2Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) 
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. There were no 
significant differences between treatments.  
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Table 5. Descriptive statistics for blood pressure by treatment, and the between-treatment differences1 
 C 
(n=30) 
LN 
(n=30) 
HN 
(n=30) 
Treatment effect2 
HN vs. C HN vs. LN 
Ambulatory blood pressure3      
Overall 24-hour      
   SBP mean, mmHg      
      Pre 126.5 ± 7.8 126.6 ± 6.4 125.6 ± 6.8   
      Post 125.9 ± 7.4 127.9 ± 8.5 126.5 ± 6.1 1.1 ± 1.3 -1.3 ± 1.3 
   DBP mean, mmHg      
      Pre 75.3 ± 8.6 75.3 ± 7.5 75.2 ± 7.8   
      Post 75.0 ± 8.3 75.7 ± 8.9 75.2 ± 7.9 0.4 ± 0.9 -0.6 ± 1.0 
   HR mean, beats/min      
      Pre 68.0 ± 8.5 69.3 ± 8.5 68.8 ± 8.3   
      Post 68.2 ± 8.3 68.6 ± 8.2 68.6 ± 8.0 -0.2 ± 1.0 0.3 ± 1.0 
Day time      
   SBP mean, mmHg      
      Pre 130.4 ± 8.0 130.7 ± 6.7 129.8 ± 7.0   
      Post 130.2 ± 7.9 132.0 ± 9.0 130.6 ± 6.4 0.7 ± 1.5 -1.3 ± 1.5 
   DBP mean, mmHg      
      Pre 78.4 ± 8.8 78.8 ± 7.9 78.5 ± 8.2   
      Post 78.3 ± 8.7 78.9 ± 9.4 78.4 ± 8.5 0.1 ± 1.1 -0.5 ± 1.1 
   HR mean, beats/min      
      Pre 70.7 ± 9.3 72.3 ± 9.0 71.5 ± 8.7   
      Post 70.6 ± 8.9 71.5 ± 8.8 71.2 ± 8.6 -0.1 ± 1.1 0.3 ± 1.1 
Night time      
   SBP mean, mmHg      
      Pre 114.9 ± 9.4 113.5 ± 7.8 112.5 ± 8.5   
      Post 112.6 ± 8.4 115.3 ± 10.4 114.2 ± 8.9 3.0 ± 1.7 -1.1 ± 1.7 
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   DBP mean, mmHg      
      Pre 66.0 ± 8.8 64.7 ± 7.4 65.3 ± 8.1   
      Post 64.8 ± 8.0 66.0 ± 8.8 65.5 ± 7.9 1.0 ± 1.0 -1.0 ± 1.1 
   HR mean, beats/min      
      Pre 60.0 ± 7.6 60.1 ± 7.6 60.5 ± 8.2   
      Post 60.7 ± 7.7 59.7 ± 7.6 60.7 ± 7.3 -0.4 ± 1.1 0.4 ± 1.2 
Home blood pressure      
Overall 4-week      
   SBP mean, mmHg      
      Pre 128.2 ± 10.2 126.9 ± 9.9 129.3 ± 10.1   
      Post 128.0 ± 9.5 126.9 ± 10.0 127.8 ± 9.7 -0.9 ± 0.7 -1.3 ± 0.8 
   DBP mean, mmHg      
      Pre 75.1 ± 8.8 74.5 ± 8.6 75.6 ± 9.0   
      Post 75.3 ± 8.6 74.5 ± 9.0 74.5 ± 8.9 -0.6 ± 0.6 -1.2 ± 0.6 
   HR mean, beats/min      
      Pre 64.6 ± 8.8 65.2 ± 9.0 65.5 ± 8.9   
      Post 65.1 ± 8.6 64.9 ± 8.8 65.7 ± 8.3 -0.2 ± 0.5 0.6 ± 0.6 
Clinic blood pressure      
   SBP mean, mmHg      
      Pre 130.4 ± 8.6 129.8 ± 10.0 130.2 ± 7.8   
      Post 130.0 ± 7.6 129.7 ± 8.4 128.4 ± 8.9 -1.4 ± 1.6 -1.9 ± 1.7 
   DBP mean, mmHg      
      Pre 77.4 ± 7.1 75.2 ± 7.6 76.6 ± 7.0   
      Post 76.5 ± 5.7 76.2 ± 8.4 75.3 ± 7.2 -0.6 ± 1.0 -2.3 ± 1.1 
   HR mean, beats/min      
      Pre 57.2 ± 7.5 56.3 ± 7.9 57.9 ± 8.0   
      Post 56.9 ± 7.3 56.9 ± 7.6 58.3 ± 8.1 -0.5 ± 1.0 -0.2 ± 1.1 
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1Results are presented as mean ± SD. n=30. C, control; LN, low nitrate; HN, high nitrate; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HR, heart rate. 
2Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) 
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. Home blood 
pressure pre-treatment values that were adjusted for were the last 7 days prior to treatment. There were no significant differences between 
treatments.  
3n=28. 
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Table 6. Descriptive statistics for pulse wave analysis and pulse wave velocity results by treatment, and the between-treatment differences1  
 C 
(n=30) 
LN 
(n=30) 
HN 
(n=30) 
Treatment effect2 
HN vs. C HN vs. LN 
Central systolic pressure, mmHg      
   Pre  119.8 ± 8.7 118.9 ± 10.2 118.8 ± 7.8   
   Post 119.1 ± 8.1 118.7 ± 8.6 117.8 ± 9.1 -0.6 ± 1.5 -1.1 ± 1.5 
Central diastolic pressure, mmHg      
   Pre  77.4 ± 7.2 75.4 ± 7.6 76.9 ± 7.1   
   Post 76.5 ± 5.3 76.3 ± 8.3 75.8 ± 7.4 -0.4 ± 1.0 -2.0 ± 1.1 
Central augmentation index, %      
   Pre  29.5 ± 11.2 27.6 ± 10.5 29.3 ± 11.4   
   Post 29.8 ± 10.2 28.5 ± 10.9 28.8 ± 10.0 -0.7 ± 1.3 0.7 ± 1.4 
Pulse wave velocity3, m/s      
   Pre 8.2 ± 1.5 8.3 ± 1.1 8.3 ± 1.1   
   Post 8.3 ± 1.3 8.3 ± 0.9 8.3 ± 1.1 -0.1 ± 0.1 -0.1 ± 0.1 
1Results are presented as mean ± SD. n=30. C, control; LN, low nitrate; HN, high nitrate. 
2Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C) 
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. There were no 
significant differences between treatments. 
3n=26. 
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Figure 1. CONSORT flow diagram for participant recruitment. 
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Figure 2. The effects of 4 weeks high and low nitrate vegetable juice on nitrate 
concentrations in (A) plasma, (B) saliva, and (C) urine; and nitrite concentrations in (D) 
plasma, (E) saliva, and (F) urine. Results are presented as estimated mean ± SE adjusted for 
pre-treatment values, treatment period and treatment order using repeated measures mixed 
modelling (n=30). 
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Figure 3. The effects of 4 weeks high and low nitrate vegetable juice on plasma 
concentrations of (A) total carotenoids, (B) lutein, (C) beta-cryptoxanthin, (D) lycopene, (E) 
alpha-carotene and (F) beta-carotene. Results are presented as estimated mean ± SE adjusted 
for pre-treatment values, treatment period and treatment order using repeated measures mixed 
modelling (n=30). Low nitrate treatment (n=29).  
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Figure 4. The effects of 4 weeks high and low nitrate vegetable juice on ambulatory, home 
and clinic measures of (A) systolic blood pressure, (B) diastolic blood pressure, and (C) heart 
rate. Results are presented as estimated mean ± SE adjusted for pre-treatment values, 
treatment period and treatment order using repeated measures mixed modelling. There were 
no significant differences between treatments. Home measures of blood pressure consisted of 
the last 7 days of treatment adjusted for the 7 days prior to pre-treatment. Ambulatory blood 
pressure (n=28); home and clinic blood pressure (n=30). C, control; L, low nitrate; H, high 
nitrate. 
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Figure 5. The effects of high and low nitrate vegetable juice on home measures of (A) 
systolic blood pressure, (B) diastolic blood pressure, and (C) heart rate for week 1, week 2, 
and week 3. Results are presented as estimated mean ± SE adjusted for the 7 days prior to pre-
treatment, treatment period and treatment order using repeated measures mixed modelling 
(n=30). There were no significant differences between treatments. 
